Three carboranyltetraphenylporphyrins containing 40 or 80
boron atoms were synthesized and evaluated for their biodistribution and toxicity in EMT-6
tumor-bearing mice.
Copper (II) meso-5,10,15,20-tetrakis[3-methoxy-4-(o-carboranylmethoxy)phenyl]
porphyrin, 6, and
copper (II) meso-5,10,15,20-tetrakis[3-hydroxy-4-(o-carboranylmethoxy)phenyl]
porphyrin, 8, are B40 congeners with different lipophilicities, each less than their B80 congener,
copper (II) meso-5,10,15,20-tetrakis[m-(3,5-di-o-carboranylmethoxybenzyloxy)phenyl]
porphyrin, 18. Two days after the last of a series of i.p.
injections in BALB/c mice bearing EMT-6 mammary
tumors, a dose of 185 mg/kg 6 (54 mg/kg B) delivered over 3.5 times the concentration of
boron to
tumor (169 microg/g B) than did 118 mg/kg 8 (36 mg/kg B), which delivered 35 microg/g B, or 87 mg/kg 18 (30 mg/kg B), which delivered 46 microg/g B. The
tumor-to-blood and
tumor-to-brain
boron concentration ratios at that time for all three
porphyrins exceeded 80:1. Two days after the last injection, there resulted moderate
thrombocytopenia that essentially disappeared two days later from 6 and 18, and mild
leukocytosis from 6, 8, and 18, all of which were clinically inconsequential. Thus, 6 may rank among the most clinically promising carboranyl
porphyrins ever made to deliver 10B to
tumors for
boron neutron-capture therapy (BNCT) that has also been tested for its toxicity in vivo.